Key result
Pulmonary vein isolation using the novel nMARQ catheter achieved acute success in 97% of patients and 98% of targeted veins, with a 13% recurrence rate over a mean follow-up of 15.9 months.
Why the study?
Does pulmonary vein isolation using a circular irrigated multielectrode mapping and ablation catheter achieve acute success and prevent recurrence of atrial tachyarrhythmia in patients with symptomatic atrial fibrillation?
Cohort (n=31)
No
Does pulmonary vein isolation using a circular irrigated multielectrode mapping and ablation catheter achieve acute success and prevent recurrence of atrial tachyarrhythmia in patients with symptomatic atrial fibrillation?
The use of a circular irrigated multielectrode mapping and ablation catheter demonstrates high acute procedural success for pulmonary vein isolation with an acceptable mid-term recurrence rate in patients with symptomatic atrial fibrillation.
May support nMARQ feasibility for PVI in symptomatic AF; leaves open comparative efficacy versus standard catheters in randomized trials.
Background: Pulmonary vein isolation (PVI) is the cornerstone of atrial fibrillation (AF) ablation in both paroxysmal and persistent AF. However, this procedure is still challenging and time consuming. Objective: The aim of this study was to present our approach for PVI using a novel circular irrigated multielectrode mapping and ablation catheter (nMARQTM) and to present acute and mid-term results. Methods: The study included 31 consecutive patients with symptomatic AF (4 had persistent and 27 had paroxysmal AF) who underwent PVI using the nMARQTM catheter. Circular ablation was guided by CT image integrated into fast anatomical map and by intra cardiac echo. Isolation of pulmonary veins was identified using the nMARQTM catheter if it was possible to advance it into the veins, otherwise Lasso catheter was used. Patients were followed up to 20 months. Results: PVI was achieved in 119 (98%) out of 121 pulmonary veins identified, and final PVI was obtained in 30 (97%) out of 31 patients. Lasso catheter was needed for PVI confirmation in 16 (52%) patients. Touch up ablation using standard catheter guided by Lasso catheter was needed in 4 (13%) patients. Pericardial tamponade occurred in 1 patient who was treated with pericardiocentesis. No other major complications were detected. During follow-up (mean 15.9 ± 3.6 months, range 9 - 20 months), 4 (13%) patients had recurrence of atrial tachyarrhythmia. Conclusion: PVI using the novel nMARQTM catheter is safe with good acute and mid-term efficacy. Long term follow up trials are needed.
No takes yet. Share an insight, caveat, or question.
Marai et al. (2016) conducted a cohort in Symptomatic Atrial Fibrillation (n=31). nMARQ circular irrigated multielectrode mapping and ablation catheter was evaluated on Acute success of pulmonary vein isolation (PVI) per patient. Pulmonary vein isolation using the novel nMARQ catheter achieved acute success in 97% of patients and 98% of targeted veins, with a 13% recurrence rate over a mean follow-up of 15.9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: